Therefore, this study aims to observe the effect of PEG-Loxe on the weight of patients with T2DM with different BMIs.<h4>Methods</h4>This single-center, retrospective real-world study included patients with T2DM, aged ≥ 18 years, and receiving PEG-Loxe/sodium-glucose cotransporter 2 inhibitor (SGLT2i). Here, SLC5A2 is linked to type 2 diabetes mellitus.